117 related articles for article (PubMed ID: 38749491)
21. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
22. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
Front Oncol; 2020; 10():654. PubMed ID: 32656072
[No Abstract] [Full Text] [Related]
24. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract][Full Text] [Related]
25. Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer.
Li C; Shi M; Lin X; Zhang Y; Yu S; Zhou C; Yang N; Zhang J; Zhang F; Lv T; Liu H; Song Y
Transl Lung Cancer Res; 2021 Feb; 10(2):776-789. PubMed ID: 33718021
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
Front Oncol; 2022; 12():974227. PubMed ID: 36523994
[TBL] [Abstract][Full Text] [Related]
27. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
[TBL] [Abstract][Full Text] [Related]
28. Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis.
Asano Y; Yamamoto N; Demura S; Hayashi K; Takeuchi A; Kato S; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Sone T; Okuda M; Matsumoto I; Yano S; Tsuchiya H
Cancer Med; 2023 Jun; 12(11):12425-12437. PubMed ID: 37076988
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.
Feng Y; Tao Y; Chen H; Zhou Y; Tang L; Liu C; Hu X; Shi Y
Thorac Cancer; 2023 Sep; 14(25):2536-2547. PubMed ID: 37551891
[TBL] [Abstract][Full Text] [Related]
30. Association between the modified lung immune predictive index and clinical outcomes of advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors combined with chemotherapy.
Xu H; Tian W; Lin X; Leong TL; Seki N; Ichiki Y; Su S; Chen J; Li Y; Ye J
J Thorac Dis; 2023 Nov; 15(11):6279-6290. PubMed ID: 38090322
[TBL] [Abstract][Full Text] [Related]
31. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
[TBL] [Abstract][Full Text] [Related]
32. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
[TBL] [Abstract][Full Text] [Related]
33. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
Front Oncol; 2021; 11():690093. PubMed ID: 34150659
[TBL] [Abstract][Full Text] [Related]
34. Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Sonehara K; Tateishi K; Araki T; Komatsu M; Akahane J; Yamamoto H; Hanaoka M
Cancer Manag Res; 2022; 14():427-435. PubMed ID: 35140520
[TBL] [Abstract][Full Text] [Related]
35. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
[TBL] [Abstract][Full Text] [Related]
36. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Kim H; Lim DH; Kwon YS; Kim MA; Park KU
Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
[TBL] [Abstract][Full Text] [Related]
37. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
[TBL] [Abstract][Full Text] [Related]
38. Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Grohé C; Blau W; Gleiber W; Haas S; Hammerschmidt S; Krüger S; Müller-Huesmann H; Schulze M; Wehler T; Atz J; Kaiser R
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):459-468. PubMed ID: 35012901
[TBL] [Abstract][Full Text] [Related]
39. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
40. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
Tian T; Yu M; Li J; Jiang M; Ma D; Tang S; Lin Z; Chen L; Gong Y; Zhu J; Zhou Q; Huang M; Lu Y
Front Oncol; 2021; 11():739090. PubMed ID: 34888234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]